RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nuo Therapeutics Stock

Nuo Therapeutics Stocks 2025

Nuo Therapeutics Stocks

42.08 M

Ticker

AURX

ISIN

US67059V2097

WKN

A2AP5P

In 2025, Nuo Therapeutics had 42.08 M outstanding stocks, a 5.19% change from the 40 M stocks in the previous year.

The Nuo Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
202342.08
202240
202130.3
202027.31
201923.72
201823.28
201714.65
20169.95
2015125.95
2014120.52
2013103.62
201281.86
201150.67
201038.67
200935.12
200832.52
200729.82
200627.47
200524.43
200418.09

Nuo Therapeutics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nuo Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nuo Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nuo Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nuo Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nuo Therapeutics Aktienanalyse

What does Nuo Therapeutics do?

Nuo Therapeutics Inc is a US-American company specializing in the development and marketing of medical products and therapies for wound healing. The company was originally founded in 2002 as Cytomedix and was renamed Nuo Therapeutics in 2016. The company's history stems from the discovery of growth factors produced by human platelets, which play an important role in wound healing. Research has shown that these growth factors can be used to expedite wound healing, making it a promising approach for the development of new medical therapies. Nuo Therapeutics aims to develop and bring innovative wound healing products and therapies to the market. The company specializes in three main areas: biosurgery, dermatology, and advanced wound care. In the biosurgery division, Nuo Therapeutics offers a range of medical products that can be used for hemostasis and wound care. This includes Nexagon® Gel, a wound treatment product based on the aforementioned growth factors, and SurgiWrapTM, a barrier membrane for the protection of surgically treated soft tissues. In the dermatology division, Nuo Therapeutics focuses on the development of therapeutic products for the treatment of skin conditions such as eczema, psoriasis, and acne. To this end, the company has entered into an agreement with a leading pharmaceutical company to develop the skincare product SECUAADTM. The advanced wound care division of Nuo Therapeutics focuses on the treatment of difficult, chronic wounds that do not heal. In this area, the company has acquired the rights to a unique technology called AurixTM, which is based on the use of growth factors from the patient's own blood. With AurixTM, Nuo Therapeutics aims to help patients with hard-to-heal wounds heal their wounds faster and more safely. The business model of Nuo Therapeutics is based on the development and commercialization of innovative medical products and therapies. The company relies on partnerships with other companies in the pharmaceutical and medical industries to support the development and marketing of its products. Nuo Therapeutics has experienced strong growth in recent years and has established itself as a key player in the market for medical wound healing products. With its innovative products and therapies, the company is well positioned to continue growing in the future and make a significant contribution to improving medical care for patients worldwide. Nuo Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Nuo Therapeutics's Shares Outstanding

Nuo Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Nuo Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Nuo Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Nuo Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Nuo Therapeutics stock

How many stocks are there of Nuo Therapeutics?

The current number of stocks of Nuo Therapeutics is 42.08 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Nuo Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Nuo Therapeutics evolved in recent years?

The number of shares of Nuo Therapeutics has increased by 5.19% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Nuo Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Nuo Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Nuo Therapeutics pay?

Over the past 12 months, Nuo Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuo Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuo Therapeutics?

The current dividend yield of Nuo Therapeutics is .

When does Nuo Therapeutics pay dividends?

Nuo Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuo Therapeutics?

Nuo Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nuo Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuo Therapeutics located?

Nuo Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Nuo Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuo Therapeutics from 3/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did Nuo Therapeutics pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of Nuo Therapeutics in the year 2024?

In the year 2024, Nuo Therapeutics distributed 0 USD as dividends.

In which currency does Nuo Therapeutics pay out the dividend?

The dividends of Nuo Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nuo Therapeutics

Our stock analysis for Nuo Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuo Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.